Novo Nordisk A/S (NVO) Return on Assets (ROA): 22.06%
Is Novo Nordisk A/S’s return on assets (ROA) high or low?
Novo Nordisk A/S's return on assets (ROA) of 22.06% is 55% below its 5-year average of 48.60%, near the low end of its 5-year range (18.87%–176.89%).
As of Thursday, June 18, 2026. 8.80% above its 12-month average of 20.27%.
NVO Return on Assets (ROA) Chart
NVO Average Return on Assets (ROA) Chart
NVO Current vs Average Return on Assets (ROA) Chart
NVO Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
22.06%
RETURN ON ASSETS (ROA) AVG TTM
20.27%
RETURN ON ASSETS (ROA) AVG 3Y
22.54%
RETURN ON ASSETS (ROA) AVG 5Y
48.60%
RETURN ON ASSETS (ROA) AVG 10Y
58.82%
RETURN ON ASSETS (ROA) AVG 15Y
29.74%
RETURN ON ASSETS (ROA) AVG 20Y
26.39%
CURRENT VS TTM AVG
+8.80%
CURRENT VS 3Y AVG
-2.14%
CURRENT VS 5Y AVG
-54.61%
CURRENT VS 10Y AVG
-62.50%
CURRENT VS 15Y AVG
-25.83%
CURRENT VS 20Y AVG
-16.40%
NVO Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $191.59B | 22.06% | 20.27% | 22.54% | 48.60% |
| Amgen Inc. (AMGN)vs › | $182.21B | 8.43% | 6.48% | 7.48% | 8.52% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $172.66B | 6.05% | 6.31% | 6.46% | 7.20% |
| Abbott Laboratories (ABT)vs › | $153.94B | 5.68% | 11.99% | 10.28% | 9.45% |
| Gilead Sciences, Inc. (GILD)vs › | $153.66B | 16.38% | 7.62% | 7.90% | 6.83% |
| Intuitive Surgical, Inc. (ISRG)vs › | $144.07B | 14.81% | 13.09% | 12.00% | 11.68% |
| Pfizer Inc. (PFE)vs › | $143.74B | 3.61% | 3.75% | 6.08% | 7.08% |
| CVS Health Corporation (CVS)vs › | $125.45B | 1.16% | 1.25% | 1.93% | 2.38% |
| Danaher Corporation (DHR)vs › | $125.40B | 4.42% | 4.68% | 5.89% | 6.01% |
| Stryker Corporation (SYK)vs › | $119.03B | 7.21% | 6.88% | 7.02% | 6.41% |
Asset Efficiency
ROA
22.1%
ROE
60.7%
Novo Nordisk A/S Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Novo Nordisk A/S (NVO)?
- The return on assets (ROA) for NVO stock is 22.06%.
- Is Novo Nordisk A/S's return on assets (ROA) high or low?
- Novo Nordisk A/S's return on assets (ROA) of 22.06% is 55% below its 5-year average of 48.60%, near the low end of its 5-year range (18.87%–176.89%).
- What is the TTM average return on assets (ROA) for Novo Nordisk A/S (NVO)?
- The TTM average return on assets (ROA) for NVO stock is 20.27%.
- What is the 3Y average return on assets (ROA) for Novo Nordisk A/S (NVO)?
- The 3Y average return on assets (ROA) for NVO stock is 22.54%.
- What is the 5Y average return on assets (ROA) for Novo Nordisk A/S (NVO)?
- The 5Y average return on assets (ROA) for NVO stock is 48.60%.
- What is the 10Y average return on assets (ROA) for Novo Nordisk A/S (NVO)?
- The 10Y average return on assets (ROA) for NVO stock is 58.82%.
- What is the 15Y average return on assets (ROA) for Novo Nordisk A/S (NVO)?
- The 15Y average return on assets (ROA) for NVO stock is 29.74%.
- What is the 20Y average return on assets (ROA) for Novo Nordisk A/S (NVO)?
- The 20Y average return on assets (ROA) for NVO stock is 26.39%.
Novo Nordisk A/S Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 18.87% |
| 2024-12-31 | 21.68% |
| 2023-12-31 | 26.61% |
| 2022-12-31 | 23.01% |
| 2021-12-31 | 24.55% |
| 2020-12-31 | 176.89% |
| 2019-12-31 | 206.43% |
| 2018-12-31 | 34.87% |
| 2017-12-31 | 37.25% |
| 2016-12-31 | 38.88% |
| 2015-12-31 | 37.97% |
| 2014-12-31 | 34.36% |
| 2013-12-31 | 35.80% |
| 2012-12-31 | 32.64% |
| 2011-12-31 | 26.43% |
| 2010-12-31 | 23.46% |
| 2009-12-31 | 19.67% |
| 2008-12-31 | 19.06% |
| 2007-12-31 | 17.86% |
| 2006-12-31 | 14.44% |
| 2005-12-31 | 13.98% |
| 2004-12-31 | 13.39% |
| 2003-12-31 | 14.13% |
| 2002-12-31 | 13.01% |
| 2001-12-31 | 13.36% |
| 2000-12-31 | 12.55% |
| 1999-12-31 | 7.79% |
| 1998-12-31 | 8.83% |
| 1997-12-31 | 8.64% |
| 1996-12-31 | 8.56% |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar